Evidence map›Paper›PMID 40071673›Full record

ReviewEuropean journal of immunology2025

Pathogenic and Nonpathogenic Antibody Responses in Allergic Diseases.

Marc Ehlers, Friederike Jönsson

Abstract readReview
In one paragraph

Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marc EhlersLaboratories of Immunology and Antibody Glycan Analysis, Institute of Nutritional Medicine, University of Lübeck and University Medical Center of Schleswig-Holstein, Lübeck, Germany.ORCID 0000-0002-5383-8603
Friederike JönssonInstitut Pasteur, Université de Paris Cité, Unit of Antibodies in Therapy and Pathology, Paris, France.

Funding

Agence National de la Recherche ANR-16-CE15-0012Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, 398859914 (EH 221/10-1) and 390884018 (Germany's Excellence Strategies- EXC 2167, Precision Medicine in Chronic Inflammation (PMI)), to ME)Deutsches Zentrum für Lungenforschung (DZL, German Center for Lung Research, 82DZLT81C6, to ME)Volkswagen Foundation 97301
6 · The paper itself

Abstract

Allergen-specific antibodies, particularly of the IgE class, are a hallmark of many allergic diseases. Yet paradoxically, (1) a proportion of healthy individuals possess allergen-specific IgE without clinical signs of allergy; (2) some, but not all, allergic individuals develop a more severe disease over time or fail to respond to allergen-specific immunotherapy; and (3) allergen-specific IgG antibodies can inhibit IgE-mediated responses but they can also induce allergic reactions. In this review, we discuss the occurrence of and transition between nonpathogenic and pathogenic allergen-specific antibody responses in the light of a two-stage model. We recapitulate different factors and scenarios that may induce different inflammatory conditions and qualitatively distinct allergen-specific T- and B-cell responses, influencing IgE origins and affinities, IgE/IgG(4) ratios, IgG effector functions, antibody glycosylation patterns, Fc and glycan-binding receptor expression and involvement, and ultimately their propensity to elicit allergic responses. Differences in these antibody characteristics may determine the onset of symptomatic allergy and the severity or remission of the disease.

Indexed as

Antibody FormationHypersensitivityImmunoglobulin EImmunoglobulin GAllergensAnimalsB-LymphocytesHumansT-LymphocytesAllergensImmunoglobulin EImmunoglobulin Gallergyantibody glycosylationIgE and IgGpathogenic versus nonpathogenic antibody responsestolerance versus immunopathology

Identifiers

PMID40071673
PMCPMC11898564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.